The fixed-dose combination of Furosemid and Spironolactone is generally applied across therapeutic domains where additional symptomatic support is needed to manage complex fluid and blood pressure issues. This medication is commonly used to help patients manage the overall symptom burden of significant fluid-related conditions, including fluid accumulation (edema) associated with advanced heart failure, liver cirrhosis, and resistant hypertension.

Diurocard is relevant for managing symptoms that interfere with daily comfort due to systemic imbalance. It assists with addressing fluid accumulation, supports the patient during difficult episodes by easing distress, and supports maintaining functional stability by easing the physical discomfort of noticeable swelling, and is intended to assist with the stabilization of elevated blood pressure. It is often used during phases when symptoms become more noticeable, providing supportive relief.

“This supportive action helps to ease shortness of breath and assists with the symptomatic discomfort related to congestion.”

---

Quick Fact: Symptom Support Overview

Domain Addressed	Key Symptom Cluster	Patient Benefit
Volume Overload States	Edema, Ascites, Vascular Congestion	Supports the easing of physical discomfort; assists with mobility
Resistant Hypertension	Elevated Blood Pressure, Systemic Strain	Contributes to pressure stabilization
Chronic Cardiac Conditions	Dyspnea, Orthopnea	Contributing to improved comfort while resting

Regulatory References

1. Rwanda FDA SmPC for Spiromide (Spironolactone/Furosemide)

Who Can and Cannot Use Diurocard?

This section defines the official population eligibility rules for Diurocard, based strictly on government regulatory documents, outlining which groups are permitted, restricted, or prohibited from using the medicine.

Official Contraindications (Must Not Use)

Diurocard is contraindicated (must not be used) in patients with specific critical health statuses, including:

• Electrolyte Imbalance: Known hyperkalemia (high blood potassium) or Addison's disease.
• Organ Function: Anuria (inability to pass urine), acute renal insufficiency, severe renal impairment, or being in hepatic coma or pre-coma.
• Hypersensitivity: Documented allergy to Furosemide, Spironolactone, or sulfonamide derivatives.

Population Eligibility Rules

Population Group	Regulatory Status
Pregnancy	Must not be taken (deemed unsafe)
Lactation	Must not be used (components appear in breast milk)
Children (< 12 years)	Not recommended (safety/efficacy not established)
Older Adults	Use with caution (requires careful monitoring)

Eligibility is conditional for certain patient groups. Individuals with severe hypotension (low blood pressure) must not use the medicine. Conditional use and monitoring are required for patients with bladder-emptying disorders or conditions like hyperuricemia (gout), which may require use to be avoided.

Diurocard’s official regulatory profile identifies distinct interaction patterns tied to its dual components. Co-administration is contraindicated with Eplerenone and other Potassium-Sparing Diuretics (such as Triamterene or Amiloride), as these combinations significantly increase the documented risk of severe hyperkalemia. Furthermore, the combination is generally advised to be avoided with agents known for organ-specific toxicity, including Aminoglycoside Antibiotics and Ethacrynic Acid, due to heightened ototoxicity risk.

Clinically relevant pharmacodynamic interactions occur with numerous agents. The risk of severe hyperkalemia is elevated when Diurocard is co-administered with other Potassium-Elevating Agents, including ACE Inhibitors, ARBs, NSAIDs, and Heparin. Concurrent use with other Antihypertensive Agents may result in additive hypotensive effects. Pharmacokinetic interactions include the Furosemide component's capacity to reduce the renal clearance of Lithium, leading to potential toxicity, and the Spironolactone component's ability to increase the half-life and plasma concentration of Digoxin.

Specific administration constraints are noted in regulatory documents. The substance Sucralfate must be administered at least two hours apart from the Furosemide component to prevent reduced absorption. Additionally, the bioavailability of Spironolactone is increased by food, and co-administration with Ethanol (Alcohol) may cause additive blood pressure lowering. The risk of specific interactions, such as hyperkalemia and ototoxicity, is documented as being increased in patients with impaired renal function.

This primary mechanism involves the simultaneous inhibition of Na^+ and Cl^- reabsorption at two distinct points of the kidney tubule: the NKCC2 transporter in the Loop of Henle and the Mineralocorticoid Receptor ( MR) in the collecting duct. This synchronized action, which combines a rapid ion channel block with a slower hormonal block, forces salt and water to remain within the tubules, leading to a reduction in extracellular fluid volume.

The drug engages complementary pathways that result in a coordinated physiological effect. Furosemid's natriuretic effect is counteracted by Spironolactone's MR antagonism, which actively reduces the expression of channels ( ENaC, ROMK) responsible for K^+ secretion. This combined mechanism modulates the compensatory Renin-Angiotensin-Aldosterone System ( RAAS), resulting in extensive fluid elimination and the maintenance of Potassium ion levels. The mechanism is physiologically constrained by the post-diuretic braking phenomenon, where the body's activated RAAS attempts to limit net volume loss, and the K^+-sparing action inherently carries the risk of excessive K^+ retention.

How Diurocard is Used: General Administration Principles

Diurocard is a fixed-dose combination product containing Furosemide and Spironolactone, administered by the oral route as a tablet. The medicine is typically reserved for cases of fluid retention (edema) that have been found to be resistant to treatment with a single diuretic agent alone, with its use contingent on prior titration of the individual components.

---

Administration and Scheduling

The standard adult dosing range is generally one to four tablets daily, with the exact dose requiring individualization to achieve the intended clinical response. The total daily dose may be taken as a single administration or divided into multiple doses. Standard administration guidelines specify that the dose should be taken with or after food to enhance the absorption of the Spironolactone component.

To minimize disruption to sleep, administration late in the day or in the evening is not recommended; doses are typically timed for breakfast and/or lunch. The tablets should be taken with sufficient liquid, such as a glass of water.

---

Population-Specific Use and Procedural Notes

This fixed-dose combination product is not suitable for use in children. For older adults, slower excretion of the component drugs may occur, necessitating careful dose selection and monitoring.

An administration constraint exists regarding co-ingestion with sucralfate: the medicine must not be taken within two hours of sucralfate to prevent a reduction in the absorption and effect of Furosemide. Treatment duration is often long-term, guided by the patient's ongoing condition and clinical response, rather than a fixed cycle.

Research evidence / Overview of Studies for Diurocard

---

Evidence for use in Chronic Heart Failure and Fluid Overload

Research examining the combination, and its two active components when studied together, has primarily focused on populations with chronic heart failure. Studies have often involved Randomized Controlled Trials (RCTs) and systematic reviews, which are typically used in research exploring how symptoms change over time. These trials were studied for outcomes related to physical discomfort and functional imbalance that arise from fluid accumulation. Researchers monitored and reported on measured changes in weight and urine output as indicators of fluid status.

Evidence for use in Liver Cirrhosis with Ascites

The combination was evaluated in patients with liver cirrhosis who experience fluid build-up (ascites), which is a condition presenting with cycles of stability and flare-ups. Research for this indication includes Randomized Comparative Studies that compared starting with the combination therapy versus using a sequential approach. The main outcomes studied focused on fluid status and volume reduction, with research exploring short-term symptom changes over several weeks.

Research for Elevated Blood Pressure (Resistant Hypertension)

The use of the combination’s aldosterone-antagonist component (Spironolactone) was studied for in the context of resistant hypertension. This refers to elevated blood pressure that remains high despite treatment with a regimen of three or more other medications. Research exploring this area includes systematic reviews and RCTs where Spironolactone was incorporated into existing multi-drug therapies. Studies monitored blood pressure readings as the primary outcomes, including measurements taken in the clinic and those collected over a full 24-hour period using ambulatory blood pressure monitoring (ABPM).

Understanding Research Gaps and Uncertainty

Despite extensive research into the two active components, several areas regarding the fixed-dose combination remain uncertain. The primary limitation is that most robust, high-quality evidence available was observed in the separate Furosemid and Spironolactone components used together, not the specific fixed-dose combination tablet. Long-term patterns are not fully established regarding the sustained measurement of symptoms and the overall course of the underlying conditions. Sample sizes were modest in some of the most specific trials for the combination tablet, meaning research is ongoing to gather more comprehensive data.

Key Studies & References

1. Cardiovascular Benefits of Spironolactone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: Insights from a Win Ratio Analysis of the TOPCAT Trial
2. Why do we use the combination of furosemide and spironolactone in the treatment of cirrhotic ascites? | AASLD

Common questions about Diurocard (FAQ)

Q: What is Diurocard and how does it work?

A: Diurocard is a brand name for the medication furosemide, which belongs to a class of drugs called loop diuretics, or 'water pills.'

It works by making your kidneys remove extra salt and water from your body through urine. This process helps to reduce swelling (edema) and lower high blood pressure.

Q: What is Diurocard used to treat?

A: Diurocard is primarily used to treat edema (swelling) caused by heart failure, liver disease, or kidney disease. It is also used alone or in combination with other medications to treat high blood pressure (hypertension).

Q: How should I take Diurocard?

A: You should take Diurocard exactly as your doctor prescribes. It is usually taken by mouth, often once or twice daily. Because it increases urination, it is often recommended to take the last dose of the day in the late afternoon, several hours before bedtime, to avoid waking up to urinate.

Diurocard can be taken with or without food. However, it is important to be consistent and always take it the same way.

Q: What should I do if I miss a dose?

A: If you miss a dose of Diurocard, take it as soon as you remember. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take two doses at the same time to make up for a missed dose.

Q: What are the common side effects of Diurocard?

A: Common side effects may include:

• Increased urination
• Dizziness, lightheadedness, or feeling faint (due to blood pressure changes)
• Muscle cramps or weakness
• Dehydration
• Hearing changes, such as ringing in the ears (tinnitus)
• Low levels of potassium or other electrolytes

Contact your healthcare provider if you experience severe side effects or if common side effects persist or worsen.

Q: Can Diurocard interact with other medicines?

A: Yes, Diurocard can interact with several other medications. It is important to tell your doctor about all prescription, over-the-counter, and herbal supplements you are taking.

Specific medications that may interact include:

• Other blood pressure medications
• Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen
• Certain antibiotics, especially aminoglycosides
• Digoxin
• Lithium

These interactions can increase the risk of side effects or reduce the effectiveness of one or both drugs.

How to Store and Dispose of Diurocard?

Regulatory standards dictate specific conditions to maintain the stability and integrity of Diurocard tablets and to ensure safe disposal.

Mandatory Storage Requirements

Storage Condition	Official Requirement
Temperature	Does not require any special temperature storage conditions.
Protection	Store in the original package and protect from light.
Child Safety	Keep strictly out of the sight and reach of children.

Disposal

Unused or expired Diurocard, or any related waste material, must be disposed of in accordance with local requirements. Government guidance strongly recommends using local drug take-back programs or following specific instructions provided by pharmaceutical collection services to prevent environmental contamination and misuse.